

Guidance for Industry

Pharmacokinetics and Pharmacodynamics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing and Labeling

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

This guidance document is being distributed for comment purposes only.

Draft released for comment on May 30, 1997.

Comments and suggestions regarding this draft guidance should be submitted within 60 days after the availability notice publishes in the *Federal Register*. All comments should be sent to Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857. Comments should be identified with the docket number listed in the *Federal Register* notice. For questions regarding this draft guidance contact Shiew-Mei Huang at 301-594-5671.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

TABLE OF CONTENTS

I.	Introduction	1
II.	Background	1
III.	Determining Whether to Conduct a Study in Patients with Impaired Renal Function	2
IV.	Study Design	3
	A. Basic “Full” Study Design	4
	B. Reduced/Staged Study Design	7
	C. Population PK Studies	7
	D. Effect of Dialysis on Pharmacokinetics	8
	E. Pharmacodynamic Assessments	9
V.	Data Analysis	9
	A. Parameter Estimation	9
	B. Modeling the Relationship Between Renal Function and PK (or PD)	10
	C. Development of Dosing Recommendations	10
VI.	Labeling	11
	A. Clinical Pharmacology	11
	B. Precautions	13
	C. Dosage and Administration	13
	D. Overdosage	15

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

GUIDANCE FOR INDUSTRY¹

**PHARMACOKINETICS AND PHARMACODYNAMICS IN
PATIENTS WITH IMPAIRED RENAL FUNCTION:
STUDY DESIGN, DATA ANALYSIS, AND
IMPACT ON DOSING AND LABELING**

I. Introduction

This guidance is intended to be used by sponsors who, during the investigational phase of drug development, intend to conduct studies to assess the influence of renal impairment on the pharmacokinetics and pharmacodynamics of an investigational drug.

II. Background

After entering the body, a drug is eliminated either by excretion or by metabolism. While elimination can occur via any of several routes, most drugs are cleared either by elimination of unchanged drug by the kidney or by metabolism in the liver. For a drug eliminated primarily via renal excretory mechanisms, impaired renal function may alter its pharmacokinetics (PK) and pharmacodynamics (PD) to an extent that the dosage regimen needs to be changed from that used in patients with normal renal function. While the most obvious type of change arising from renal impairment is a decrease in renal excretion (or possibly renal metabolism) of a drug or its metabolites, renal impairment has also been associated with other changes, such as changes in hepatic metabolism, plasma protein binding, and drug distribution. These changes may be particularly prominent in patients with severely impaired renal function and have been observed even when the renal route is not the primary route of elimination of a drug. Thus, for most drugs that are likely to be administered to patients with renal impairment, PK/PD characterization may need to be assessed in patients with renal impairment in order to provide rational dosing recommendations.

¹This guidance has been prepared by the Renal Impairment Working Group in the Clinical Pharmacology Section of the Medical Policy Coordinating Committee in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration. This guidance document represents the Agency's current thinking on this subject. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both. Additional copies of this draft guidance document are available from the Drug Information Branch, Division of Communications Management, HFD-210, 5600 Fishers Lane, Rockville, MD 20857, (Tel) 301-827-4573, (Internet) <http://www.fda.gov/cder/guidance.htm>.

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

The objectives of this guidance are to make recommendations regarding:

- When studies of PK in patients with impaired renal function should be performed—and conversely, when they may be unnecessary;
- The design and conduct of PK/PD studies in patients with impaired renal function;
- The design and conduct of PK/PD studies in end stage renal disease (ESRD) patients treated with hemodialysis;
- The analysis and reporting of the results of such studies;
- Representation of these results in approved product labeling.

III. Determining Whether to Conduct a Study in Patients with Impaired Renal Function

When Studies May Be Important:

A PK study in patients with impaired renal function is recommended when: 1) renal impairment is likely to significantly alter the PK or PD of a drug or its active metabolites; 2) a dosage adjustment is likely to be necessary for safe and effective use in such patients; and 3) the drug is likely to be used in such patients. In particular, a study in patients with impaired renal function is recommended when the drug or its active metabolites exhibit a narrow therapeutic index and when excretion and/or metabolism occurs primarily via renal mechanisms (excretion or metabolism). A study should also be considered when a drug or an active metabolite exhibits a combination of high hepatic clearance (relative to hepatic blood flow) and significant plasma protein binding. In this setting, renal impairment could induce a significant increase in the unbound concentrations due to a decreased plasma protein binding coupled with little or no change in the total clearance (decrease in unbound clearance).

When Studies May Not Be Important:

For some drugs, renal impairment is not likely to alter PK or PD enough to justify dosage adjustment. In such cases, a study to confirm that prediction may be helpful but is not necessary. If a study is not conducted, the labeling should indicate that the impact of renal impairment was not studied, but that an effect requiring dosage adjustment is not likely to be present. Current knowledge suggests that the following drug properties may justify this approach:

- Drug and active metabolites with a relatively wide therapeutic index and that are primarily eliminated via hepatic metabolism;
- Drug and active metabolites that are primarily eliminated via biliary excretion;
- Gaseous or volatile drug and active metabolites that are primarily eliminated via the lungs;
- Drugs intended only for single dose administration.

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

Controversy exists regarding the impact of severe renal impairment on hepatic metabolism, so a renal impairment study is still considered desirable for drugs eliminated primarily via hepatic metabolism unless it also has a relatively wide therapeutic index.

Even when renal impairment is likely to have little or no effect on a drug's PK, it is usually desirable to study the PK impact of dialysis. It is conceivable that patients on dialysis may require greater doses of such drugs than patients with normal renal function. This is discussed further in section III.D.

IV. Study Design

Safety and efficacy of a drug are generally established for a particular dosage regimen (or range of dosage regimens) in Phase 3 clinical trials involving relatively typical representatives from the target patient population. More often than not, individuals with significantly impaired renal function are explicitly excluded from participation in these studies, although there may be a sufficient range of function to obtain an initial estimate of the effects of decreased renal function. The primary goal of the recommended study in patients with impaired renal function is to determine if the PK or PD is altered to such an extent that the dosage should be adjusted from that established in the Phase 3 trials. Thus, the study should reasonably focus on comparing patients with renal impairment to patients with renal function that is typical of the usual patient population—not necessarily to normal healthy young volunteers. The term “normal renal function” is subsequently used to refer to typical patients with renal function that is expected for their age and weight.

The strategy used in this section is to describe the basic “full” study design that could be applied to most drugs whose pharmacodynamics (i.e., concentration-response relationship) are known to be unaffected by renal impairment or whose therapeutic indices (e.g., TD50/ED50) are sufficiently large to preclude safety concerns. Then cases are identified for which some elements of the full study design may be simplified or excluded depending on the properties of the drug and its anticipated use in the target patient population.

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

A. Basic “Full” Study Design

1. Study Participants

Ideally, the control or normal renal function group in this study should be representative of a typical patient population for the drug to be studied. In particular, it should not consist of normal healthy young male volunteers if the typical patient population is made up of older people, including women. However, it is recognized that it may be difficult to enroll enough individuals with varying degrees of renal impairment who are also patients with the condition for which the drug is indicated. An acceptable alternative would be to use volunteers who are comparable to the typical patient population with respect to renal function and other factors such as age and gender. For example, a logical control group for a drug intended for treatment of Alzheimer’s disease would be otherwise healthy elderly male and female patients whose baseline renal function would clearly not be comparable to young healthy male volunteers.

The study may also include a group of subjects with greater renal function than the normal renal function control group (e.g., a group of healthy young volunteers). The resulting wider range of renal function enhances the ability to detect and characterize the effect of renal function on PK. It also allows for the possibility that the actual patient population may include some people with greater renal function than the control group. However, recommendations about dosage adjustments should be based on comparison to the normal renal function control group, not necessarily to the group with the greatest renal function.

To ensure adequate representation of patients with various degrees of renal impairment, recruitment of approximately equal numbers of patients from each of the following groups is suggested:

Group	Description	RF/RF _{norm}
1	Normal renal function	> 0.8
2	Mild renal impairment	0.4-0.8
3	Moderate renal impairment	0.1-0.4
4	Severe renal impairment (ESRD)	<0.1

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

RF refers to a measure of renal function. Currently this is usually creatinine clearance (CL_{cr}). RF_{norm} is the mean or typical value of RF for patients with normal renal function. The renal function values given above for the boundaries between groups are provided for approximate guidance and may be rounded off to reasonable values for the actual study, e.g., creatinine clearance values in multiples of 5 or 10 mL/min.

The renal function groups should be comparable to each other with respect to age, gender, and other factors with significant potential to affect the PK/PD of the drug to be studied, e.g., smoking, alcohol intake, concomitant medications, ethnicity.

The number of patients enrolled in the study should be sufficient to detect PK differences that are large enough to warrant dosage adjustments. This depends on the PK variability of the drug as well as the PK/PD relationships for both therapeutic and adverse responses (therapeutic index).

2. Drug Administration

A single dose study is satisfactory for cases where there is clear prior evidence that multiple dose PK is accurately predictable from single dose data for all chemical species of interest (drug and potentially active metabolites). This would be the case when the drug and active metabolites exhibit linear and time-independent PK at the concentrations anticipated in the patients to be studied. A multiple dose study is desirable when the drug or an active metabolite is known to exhibit nonlinear or time-dependent PK.

For single dose studies, the same dose may usually be administered to all patients in the study regardless of renal function because the peak concentration is generally not greatly affected by renal function. For multiple dose studies, it may be necessary to use lower or less frequent doses as renal function decreases to prevent accumulation of drug and metabolites to unsafe levels. The dosage regimen may be adjusted based on the best available pre-study estimates of the PK of the drug and its active metabolites in patients with impaired renal function. Alternatively, a concentration-controlled study design could be employed. In other words, the study could be conducted to achieve a specific target concentration using therapeutic drug monitoring procedures. In multiple dose studies, the dosing should usually be continued for a sufficiently long duration to achieve steady state. A loading dose may be desirable to facilitate this, particularly if the elimination half-life is greatly prolonged in patients with renal impairment.

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

3. Sample Collection and Analysis

Plasma (and optionally urine) samples should be analyzed for parent drug and any metabolites with known or suspected activity (therapeutic or adverse). This is particularly important in patients with impaired renal function since renally excreted metabolites can accumulate to a much higher degree in such patients. The frequency and duration of plasma sampling and urine collection should be sufficient to accurately estimate the relevant pharmacokinetic parameters for the parent drug and its active metabolites (see the section on Data Analysis).

Plasma protein binding is often altered in patients with impaired renal function. For systemically active drugs and metabolites, the unbound concentrations are generally believed to determine the rate and extent of delivery to the sites of action. This leads to the recommendation that the PK should be described and analyzed with respect to the unbound concentrations of the drug and active metabolites. Ideally, unbound concentrations should be measured in each plasma sample. However, if the binding is concentration-independent and is not affected by metabolites or other time-varying factors, then the fraction unbound may be determined using a limited number of samples or even a single sample from each patient. The unbound concentration in each sample is then estimated by multiplying the total concentration by the fraction unbound for the individual patient. For drugs and metabolites with a relatively low extent of plasma protein binding (e.g., a fraction unbound greater than 75%), alterations in binding due to impaired renal function are small in relative terms. In such cases, it is sufficient to describe and analyze the PK in terms of total concentrations.

4. Measures of Renal Function

Currently, creatinine clearance is widely used in patient care settings as a measure of renal function. Consequently, it is more practical than most other alternatives as a criterion for making dosage adjustments in outpatient and inpatient settings. In a controlled study setting, it is recommended that creatinine clearance should be calculated based on cumulative creatinine excretion in urine and serum creatinine levels.

Other measures of renal function that can differentially characterize glomerular filtration or renal tubular secretion may provide additional mechanistic understanding of the effect of renal impairment on PK. Such methods are encouraged as useful additions, but not as alternatives to methods that are more readily available in patient care settings, such as creatinine clearance or serum creatinine concentration.

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

B. Reduced/Staged Study Design

The basic “full” study design is structured to comprehensively characterize the effect of renal impairment on PK. It presumes that the drug’s PK is likely to change as renal function decreases. The full study then provides the information needed to rationally adjust doses for patients with impaired renal function.

If there is good reason to believe that renal impairment does not affect PK to a degree sufficient to warrant dosage adjustment, then it can be argued that the full study is larger and more complex than necessary. An acceptable alternative is an adaptive two stage approach. Stage 1 consists of studying only patients at the extremes of renal function, i.e., patients with normal (Group 1) and severely impaired (Group 4) renal function. If the results confirm that renal impairment does not alter PK to an extent that warrants dosage adjustment, then no further study is warranted. However, if the results do not strongly support such a conclusion, then in Stage 2 the intermediate renal function groups (mild and moderate renal impairment) should also be studied. The results of both stages should be combined for all subsequent data analysis.

C. Population PK Studies

A population PK screen of patients participating in Phase 2/Phase 3 clinical trials may be used to assess the impact of various covariates on the PK of a drug. Typically, each patient is only sparsely sampled to obtain plasma drug concentration data. Techniques such as nonlinear mixed effects modeling may be used to model the relationship between the various covariates and PK parameters. A measure of renal function such as creatinine clearance may be one of the covariates. Therefore, it may be possible to model the relationship between creatinine clearance and PK parameters such as the apparent clearance of the drug (CL/F).

In principle such a population PK study design and analysis can be an acceptable alternative if it retains some of the critical components of the more conventional studies described in previous sections, e.g.,

- A sufficient number of patients and a sufficient representation of a range of renal function that the study could detect PK differences large enough to warrant dosage adjustment;
- Measurement of unbound concentrations when appropriate;
- Measurement of parent drug and potentially active metabolites.

Such features are particularly critical if the sponsor intends to use the results to support a claim that no dosage adjustment is required for patients with impaired renal function.

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

Patients with severe renal impairment are often excluded or poorly represented in population PK studies. When that occurs for a drug that is likely to be administered to such patients, it is recommended that a separate study be conducted to assess PK in patients with severe renal impairment, i.e., a study like Stage 1 of the reduced/staged study design described in the previous section. The data from both sources should be combined to construct an overall assessment of the effect of renal impairment.

D. Effect of Dialysis on Pharmacokinetics

Dialysis, particularly hemodialysis, may significantly affect the PK of a drug to an extent that dosage adjustment is appropriate. The need for dosage adjustment results when a significant fraction of the drug or active metabolites in the body is removed by the dialysis process. In such cases, a change in the dosage regimen, such as a supplemental dose following the dialysis procedure, may be required.

For drugs that are likely to be administered to end stage renal disease (ESRD) patients treated with dialysis, it is desirable that PK be studied in such patients under both dialysis and non-dialysis conditions to determine the extent to which dialysis contributes to the elimination of the drug and potentially active metabolites. Primary questions to be addressed are whether the dosage should be adjusted as a consequence of dialysis and, if so, by how much. The results of the study also provide valuable insight regarding the value of dialysis for treatment of overdose.

The assessment of PK in dialysis may be integrated with the PK in renal impairment study described above, or it may be conducted as a separate study.

Since intermittent hemodialysis is the most commonly used dialysis method in ESRD patients, it is usually the most important method to be evaluated. It may also be desirable to study PK in patients treated with CAPD, the next most common form of dialysis. A study in CAPD patients is recommended if the drug is likely to be used in such patients and CAPD is likely to significantly affect PK.

In general, a study of the effect of dialysis on PK may be omitted if the dialysis procedure is unlikely to result in significant elimination of drug or active metabolites. This is arguable for drugs and active metabolites that have a large unbound volume of distribution (V_u) or a large unbound nonrenal clearance ($CL_{NR,u}$).

If the drug and metabolites have a large unbound volume of distribution (V_u), then only a small fraction of the amounts in the body would be removed by dialysis. For example, if V_u is greater than 350 L, then less than 10% of the amount initially in the body could

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

be removed by 3 hours of high flux hemodialysis with an unbound dialysis clearance of 200 mL/min.

If the drug and metabolites have a large unbound nonrenal clearance ($CL_{NR,u}$), then dialysis contributes a relatively small amount to the overall unbound clearance. For example, if $CL_{NR,u}$ is greater than 120 mL/min, then 3 hours of high flux hemodialysis with an unbound dialysis clearance of 200 mL/min administered every 2 days would contribute less than 10% to the overall clearance.

E. Pharmacodynamic Assessments

If the drug is known or suspected to have an altered unbound concentration-response relationship in patients with impaired renal function or if the activity of metabolites at the concentrations found in such patients is unknown, it may be appropriate to include pharmacodynamic assessments (e.g., safety and/or efficacy) in the trials described above. Such a decision should be discussed with the review division and should be based on the pharmacological characteristics of the drug and metabolites (e.g., extent of protein binding, therapeutic index), and the behavior of other drugs in the same class in patients with renal impairment.

V. Data Analysis

The primary intent of the data analysis is to assess whether dosage adjustment is required for patients with impaired renal function, and, if so, to develop dosing recommendations for such patients based on measures of renal function. The data analysis typically consists of the following steps:

- Estimation of PK (or PD) parameters
- Mathematical modeling of the relationship between measures of renal function and the PK (or PD) parameters
- Development of dosing recommendations including an assessment of whether dosage adjustment is warranted in patients with impaired renal function

A. Parameter Estimation

Plasma concentration data (and urinary excretion data if collected) should be analyzed to estimate various parameters describing the PK of the drug [area under the plasma concentration curve (AUC), peak concentration (C_{max}), apparent clearance (CL/F), renal clearance (CL_R), apparent volume of distribution (V_z/F or V_{ss}/F), terminal half-life ($t_{1/2}$)] and its active metabolites [area under the plasma concentration curve (AUC), peak concentration (C_{max}), renal clearance (CL_R), terminal half-life ($t_{1/2}$)]. If possible, it is

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

usually preferred that the parameters be expressed in terms of unbound concentrations, e.g., apparent clearance relative to the unbound drug concentrations ($CL_u/F = D/AUC_u$ where the subscript 'u' indicates unbound drug). Noncompartmental and/or compartmental modeling approaches to parameter estimation may be employed.

B. Modeling the Relationship Between Renal Function and PK (or PD)

The objective of this step is to construct mathematical models for the relationships between RF (measures of renal function, particularly creatinine clearance (CL_{cr})) and relevant PK parameters. The PK parameters of greatest interest are usually the apparent unbound clearance (CL_u/F) or the dose-normalized area under the unbound concentration curve (AUC_u/D), and the dose-normalized peak unbound concentration ($C_{max,u}/D$) for the drug and active metabolites. The intended result is a model that can successfully predict PK behavior given information about renal function. Generally, this involves a regression approach in which RF and the PK parameters are treated as continuous variables. This is usually preferred to an analysis in which RF is treated as a categorical variable corresponding to the normal, mild, moderate, and severe renal impairment groups. The most commonly used model is a linear relationship between CL_{cr} and the total or renal clearance of the drug. Other models are acceptable if adequately supported by the data and/or mechanistic arguments.

The intent of the modeling exercise is to provide a rational quantitative basis for dosage recommendations in the drug's labeling. The model itself may be described in the clinical pharmacology section of the labeling.

The reported modeling results should include estimates of the parameters of the chosen model as well as measures of their precision (standard errors or confidence intervals). Prediction error estimates are also desirable, e.g., confidence bounds for prediction of AUC_u/D for the drug and its active metabolites over a range of RF.

C. Development of Dosing Recommendations

Specific dosing recommendations should be constructed based on the study results using the aforementioned model for the relationships between RF and relevant PK parameters. Typically the dose is adjusted to produce a comparable range of unbound plasma concentrations of drug or active metabolites in both normal patients and patients with impaired renal function. Simulations are encouraged as a means to identify doses and dosing intervals that achieve that goal for patients with different levels of renal function.

For some drugs, even severe renal impairment may not alter PK (or PD) sufficiently to warrant dosage adjustment. Data analysis to support such a claim should convincingly

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

indicate that the PK parameters most relevant to therapeutic outcome have values in patients with severe renal impairment that are similar to those in normal patients. The difference in parameter values between the two groups should be small enough that dosage adjustment is not necessary to assure comparable safety and efficacy in the patients with impaired renal function. One approach would be to estimate a confidence interval for the ratio of a PK parameter value for patients with severe impairment relative to the value for patients with normal renal function, e.g., $(AUC_{u,severe}/AUC_{u,normal}) \cdot (D_{normal}/D_{severe})$. The confidence interval may be estimated using any defensible method including methods based on the model for the RF/PK relationship. If comparable efficacy and safety are expected for the entire range of PK parameter values covered by the confidence interval, then it is reasonable to conclude that no dosage adjustment is required. Otherwise dosage adjustment may be appropriate. If the confidence interval is so wide that a clear conclusion cannot be reached, then it may be desirable to study a larger number of patients with renal impairment.

VI. Labeling

Overview: The label should reflect the data pertaining to the effect of renal function on the pharmacokinetics and pharmacodynamics (if known) obtained from studies conducted. The various permutations of intrinsic drug characteristics and the effect of renal impairment on drug performance preclude precise specification of how such drugs should be labeled. The following comments offer general suggestions on which sections should include standardized information and how such information should be structured.

A. Clinical Pharmacology

1. Pharmacokinetics subsection

Information in this section should include:

- Mechanism of renal elimination (e.g., filtration, secretion, active reabsorption)
- Percent of drug that is eliminated by renal excretion and whether it is eliminated unchanged or as metabolites
- Disposition of metabolites in patients with impaired renal function (if applicable)
- Effects of renal impairment on protein binding of parent drug and metabolites (if applicable)
- Effects of changes in urinary pH or other special situations that should be mentioned (e.g., tubular secretion inhibited by probenecid)

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

- If applicable, the effects of impaired renal function on stereospecific disposition of enantiomers of a racemic drug product should be described if there is evidence of differential stereoisomeric activity or toxicity

2. Special Populations Subsection

This section should recapitulate, in brief, the pharmacokinetic changes found in various degrees of renal impairment and address any issues of altered pharmacodynamics and dosing adjustments for patients with varying degrees of renal impairment. This information should be based on the studies performed as described in this guidance. Reference should be made to the PRECAUTIONS and DOSAGE AND ADMINISTRATION sections.

The following text provides examples of appropriate wording for this section.

The simplest situation involves drugs for which impaired renal function has little or no effect on PK or PD:

“Impaired renal function has no influence on _____ pharmacokinetics or pharmacodynamics (if known) and no dosing adjustment is required.”

Similarly, for drugs whose PK or PD is influenced by renal impairment, the following statement may be modified as appropriate and in accordance with what is known about the drug (e.g., racemate with different activity of stereoisomers, active or toxic metabolite) and from the studies performed in accordance with this guidance:

“The disposition of _____ was studied in patients with varying degrees of renal function. Elimination of the drug (and metabolite, if applicable) is significantly correlated with the creatinine clearance. Total body clearance of (unbound, if applicable) _____/metabolite was reduced in patients with impaired renal function by --- % in mild ($CL_{Cr} = \text{---} \text{ mL/min}$), --- % in moderate ($CL_{Cr} = \text{---} \text{ mL/min}$) and --- % in severe renal impairment ($CL_{Cr} = \text{---} \text{ mL/min}$), and --- % in patients under dialysis compared to normal subjects ($CL_{Cr} > \text{---} \text{ mL/min/1.73 m}^2$). The terminal half-life of _____/metabolite is prolonged by -, -, -, and -fold in mild, moderate, and severe renal impairment, respectively. [Alternatively, the relationship between renal function and the PK parameters may be described in terms of equations, e.g., a linear equation relating unbound clearance and CL_{Cr} .] Protein binding of _____/metabolite is/is not affected by decreasing renal function. The drug/metabolite accumulates in patients with impaired renal function on chronic

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

administration. The pharmacologic response is/is not affected by renal function. Approximately --- % of the drug/metabolite in the body was cleared from the body during a standard 4-hour hemodialysis procedure. The dosage should be reduced in patients with impaired renal function receiving _____ and supplemental doses should/should not be given to patients after dialysis. (See DOSAGE AND ADMINISTRATION)."

B. Precautions

Use in Patients with Impaired Renal Function: If the effects of renal impairment result in clinically important changes in drug pharmacokinetics and/or pharmacodynamics, this should be included in the PRECAUTIONS section with reference to DOSAGE AND ADMINISTRATION. If a drug is known to have a low therapeutic index (i.e., toxic dose/effective dose is small), consideration should be given to including a statement in the WARNINGS section.

C. Dosage and Administration

As appropriate, the following statement may be considered:

"The influence of impaired renal function on _____ pharmacokinetics or pharmacodynamics (if known) is sufficiently small that no dosing adjustment is required."

However, for many drugs, impaired renal function may require dosing adjustments. In such cases, the following information should be included:

1. A statement describing the relationship between _____ clearance and endogenous creatinine clearance.
2. If there is a need for dosage adjustment, the following statement may be adapted as appropriate:

"_____ dosing must be individualized according to the patient's renal function status. Refer to the following table for recommended doses and adjust the dose as indicated. In order to use this dosing table, an estimate of the patient's creatinine clearance (CL_{Cr}) in mL/min is required. CL_{Cr} in mL/min may be estimated from a spot serum creatinine (mg/dL) determination using the following formula:

$$CL_{Cr} \approx \frac{[140 - \text{age (years)}] \times \text{weight (kg)}}{72 \times \text{serum creatinine (mg/dL)}} \{ \times 0.85 \text{ for female patients} \}$$

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

The serum creatinine should represent a steady-state of renal function. The following formulas are preferable for children (to be included if the drug has a pediatric indication):

$$\text{Infants less than one year:} \quad CL_{Cr} \approx \frac{0.45 \times \text{length (cm)}}{\text{serum creatinine (mg/dL)}}$$

$$\text{Children 1–12 years:} \quad CL_{Cr} \approx \frac{0.55 \times \text{length (cm)}}{\text{serum creatinine (mg/dL)}}$$

3. The dosing adjustment regimen should then be represented in tabular format (see example below).

Group	Creatinine Clearance (mL/min)	Dosage (mg)	Frequency
Normal	> __	x	Every x hours
Mild	__–__		
Moderate	__–__		
Severe	< __		
ESRD patients using dialysis			Supplemental dose should be given after dialysis.

4. Special consideration should be given to combination drug products. Dosing adjustment should be recommended according to the degree of renal impairment, provided that there is sufficient information to indicate that the pharmacokinetics/pharmacodynamics of the individual components of the combination product are comparably affected by impaired renal function. In situations in which this does not apply, the following statement should be adapted:

“Because the doses of this fixed combination product cannot be individually titrated and impaired renal function results in a reduced clearance of component A to a much greater extent than component B, combination drug should generally be avoided in patients with suspected or documented renal impairment (see WARNINGS or PRECAUTIONS, as appropriate).”

D. Overdosage

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

Although the primary objective of a hemodialysis study is to evaluate the need for dosing adjustments in ESRD, additional information regarding the value of hemodialysis in overdose situations may reasonably be garnered from such studies (if performed). In situations in which this information is known, the following wording may be adapted as appropriate:

“_____ is not eliminated to a therapeutically significant degree by hemodialysis.”

or

“Standard hemodialysis procedures result in significant clearance of _____ and should be considered in cases of life-threatening overdose.”

DRAFT GUIDANCE — NOT FOR IMPLEMENTATION

COMIS # 1781

Drafted:

Reviewed: JAxelrad: HFD-5: 5/25/97

Proofed: NDerr: HFD-5: 5/27/97